

1       **Distinct impact of IgG subclass and Fc-FcγR interaction on autoantibody**  
2                           **pathogenicity in different IgG4-mediated diseases**

3     Yanxia Bi<sup>1,2</sup>, Jian Su<sup>3,4</sup>, Shengru Zhou<sup>5</sup>, Yingjie Zhao<sup>1,2</sup>, Yan Zhang<sup>1,2</sup>, Huihui Zhang<sup>1,2</sup>,  
4     Mingdong Liu<sup>1,2</sup>, Aiwu Zhou<sup>2</sup>, Meng Pan<sup>5</sup>, Yiming Zhao<sup>3,4\*</sup>, Fubin Li<sup>1,2,6\*</sup>

5     <sup>1</sup>Shanghai Institute of Immunology, Faculty of Basic Medicine, Shanghai Jiao Tong University  
6     School of Medicine, Shanghai 200025, China

7     <sup>2</sup>Key Laboratory of Cell Differentiation and Apoptosis of Chinese Ministry of Education,  
8     Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China

9     <sup>3</sup>Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou  
10    215006, China

11    <sup>4</sup>Collaborative Innovation Center of Hematology, Soochow University, Suzhou 215006, China

12    <sup>5</sup>Department of Dermatology, Rui Jin Hospital, Shanghai Jiao Tong University School of  
13    Medicine, Shanghai 200025, China

14    <sup>6</sup>Leading contact: Fubin Li (fubin.li@sjtu.edu.cn)

15    \* Address correspondence to Fubin Li (0086-18918925314; fubin.li@sjtu.edu.cn) or Yiming  
16    Zhao (0086-13862045330; zhaoyimingbox@163.com)

17

18 **Abstract**

19 IgG4 is the least potent human IgG subclass for the Fc $\gamma$ R-mediated antibody effector function  
20 and is considered anti-inflammatory in the context of prolonged inflammation and allergic  
21 responses. Paradoxically, IgG4 is also the dominant IgG subclass of pathogenic autoantibodies in  
22 IgG4-mediated diseases. Here we show that the IgG subclass and Fc-Fc $\gamma$ R interaction have a  
23 distinct impact on the pathogenic function of autoantibodies in different IgG4-mediated diseases.  
24 While IgG4 and its weak Fc-Fc $\gamma$ R interaction have an ameliorative role in the pathogenicity of  
25 anti-ADAMTS13 autoantibodies isolated from thrombotic thrombocytopenic purpura (TTP)  
26 patients, they have an unexpected exacerbating effect on anti-Dsg1 autoantibody pathogenicity in  
27 pemphigus foliaceus (PF) models. Strikingly, a non-pathogenic anti-Dsg1 antibody variant  
28 optimized for Fc $\gamma$ R-mediated effector function can attenuate the skin lesions induced by  
29 pathogenic anti-Dsg1 antibodies by promoting the clearance of dead keratinocytes. These studies  
30 suggest that IgG effector function contributes to the clearance of autoantibody-Ag complexes,  
31 which is harmful in TTP, but beneficial in PF and may provide new therapeutic opportunity.

## 32 Introduction

33 IgG4, the least expressed IgG subclass in humans, is a highly relevant IgG subclass in a range of  
34 IgG4-mediated autoimmune diseases and IgG4-related diseases, both of which are still  
35 expanding (Huijbers, Plomp, van der Maarel, & Verschuuren, 2018; Koneczny, 2018; Umehara  
36 et al., 2017). It is generally accepted that IgG4 has the poorest effector function among all human  
37 natural IgG subclasses and is anti-inflammatory (Lighaam & Rispens, 2016). This is due to the  
38 unique features of IgG4, including its low affinity to Fc $\gamma$ Rs and lack of capacity to activate  
39 complements, as well as its reduced ability to form immune complex due to a unique process  
40 referred to as Fab-arm exchange (Lighaam & Rispens, 2016; Vidarsson, Dekkers, & Rispens,  
41 2014). The Fab-arm exchange between different IgG4 antibodies results in the formation of  
42 heterodimeric IgG4 molecules (*i.e.*, bi-specific IgG4 antibodies) that only allow monovalent  
43 binding (Koneczny, 2018; Lighaam & Rispens, 2016). Given these features, it has been  
44 speculated that the choice of IgG4 subclass in autoantibodies in various relevant autoimmune  
45 diseases may be protective by reducing or preventing the pathogenic function of more harmful  
46 antibody classes or subclasses (Rihet, Demeure, Dessein, & Bourgois, 1992). IgG4  
47 autoantibodies targeting the acetylcholine receptor (AChR) have been reported to protect  
48 monkeys from myasthenia gravis induced by matched IgG1 autoantibodies (van der Neut  
49 Kolfshoten et al., 2007). Allergen-specific IgG antibodies derived from hyperimmune  
50 beekeepers, mostly IgG4, have been reported to be protective in allergy patients (Devey, Lee,  
51 Richards, & Kemeny, 1989) and mouse models (Schumacher, Egen, & Tanner, 1996).  
52 Phospholipase A<sub>2</sub> (PLA) specific autoantibodies in patients with bee venom allergy switched  
53 from IgE to IgG4 after effective antigen-specific immunotherapy (Akdis & Akdis, 2011; Devey  
54 et al., 1989).

55 IgG4-mediated autoimmune diseases represent a unique category of more than ten autoimmune  
56 conditions featured by the accumulation of pathogenic antigen-specific IgG4 autoantibodies. The  
57 pathogenic function of IgG4 autoantibodies has been either well established or highly suspected  
58 in the majority of these diseases (Huijbers et al., 2018; Koneczny, 2018). Among them,  
59 thrombotic thrombocytopenic purpura (TTP) and pemphigus foliaceus (PF) are two well-studied  
60 examples, in which both disease-triggering autoantibodies and their antigenic targets have been  
61 identified. In PF, autoantibodies bind to Dsg1 (desmoglein 1), a desmoglein protein highly  
62 expressed in the superficial layers of the epidermis and essential for adhesion between  
63 neighboring keratinocytes, and result in the loss of cell-cell adhesion and the blistering of skin  
64 (Anhalt, Labib, Voorhees, Beals, & Diaz, 1982; Korman, Eyre, Klaus-Kovtun, & Stanley, 1989;  
65 Rock et al., 1989). ADAMTS13 (a disintegrin and metalloproteinase with a thrombospondin type  
66 1 motif, member 13), the critical enzyme maintaining the homeostasis of von Willebrand Factor  
67 (vWF) in the plasma, is targeted by autoantibodies in acquired TTP (Zheng, 2015). In both PF  
68 and TTP patients, IgG4 is a major autoantibody subclass, and its levels correlate with disease  
69 activities (Ferrari et al., 2009; Rock et al., 1989; Sinkovits et al., 2018; Warren et al., 2003).  
70 Importantly, polyclonal anti-Dsg1 and ADAMTS13 enriched from patient plasma, as well as  
71 monoclonal anti-Dsg1 and -ADAMTS13 autoantibodies isolated from patients, are pathogenic in  
72 both in vitro assay and animal models (Huijbers et al., 2018; Koneczny, 2018). These studies,  
73 together with the study of other IgG4-mediated diseases and IgG4-related diseases (Shiokawa et  
74 al., 2016), have established that IgG4 autoantibodies are pathogenic and highly relevant to the  
75 development of these diseases (Huijbers et al., 2018; Koneczny, 2018).  
76 It is, however, not clear whether the IgG4 subclass in these IgG4 autoantibodies has any impact  
77 on their pathogenicity. Most studies supported the notion that IgG4 is the most prevalent IgG



78 subclass in anti-ADAMTS13 autoantibodies and is associated with disease relapse (Ferrari et al.,  
79 2009; Sinkovits et al., 2018). At the same time, IgG1 and IgG3 autoantibody levels appear to  
80 have a stronger correlation with disease severity in acquired TTP patients during the acute phase  
81 (Bettoni et al., 2012). In contrast, pathogenic anti-Dsg1 autoantibodies often have the IgG4  
82 subclass, whereas non-pathogenic anti-Dsg1 autoantibodies often have the IgG1 subclass in  
83 endemic PF patients (Aoki, Rivitti, Diaz, & Cooperative Group on Fogo Selvagem, 2015;  
84 Warren et al., 2003). However, it is also reported that these pathogenic and non-pathogenic anti-  
85 Dsg1 autoantibodies have different binding epitopes (Aoki et al., 2015; Li, Aoki, Hans-Filho,  
86 Rivitti, & Diaz, 2003). Therefore, despite that IgG4 autoantibodies are pathogenic, and that some  
87 autoantibodies isolated from IgG4-mediated diseases (anti-Dsg1, e.g.) are pathogenic in the form  
88 of scFv and Fab fragments (Ishii, Lin, Siegel, & Stanley, 2008; Rock, Labib, & Diaz, 1990;  
89 Yamagami et al., 2009), it does not rule out the possibility that the choice of IgG4 in these  
90 autoantibodies is a protective mechanism against the otherwise more harmful antibody classes or  
91 subclasses.

92 Furthermore, it appears that antibodies with different modes of action, including effector  
93 antibodies, agonistic, and blocking antibodies, could be impacted by IgG subclasses and Fc-FcγR  
94 interactions in different ways. Both humans and mice have activating and inhibitory FcγRs that  
95 mediate or inhibit antibody effector functions, respectively. Either ablating activating FcγRs  
96 expression or ectopically overexpressing inhibitory FcγRIIB can protect autoimmune mice from  
97 premature mortality (Clynes, Dumitru, & Ravetch, 1998; McGaha, Sorrentino, & Ravetch,  
98 2005), as well as arthritic antibody-induced joint inflammation in murine models (Ji et al., 2002).  
99 Studies of blocking and agonistic antibodies, which exert their function in entirely different

100 ways, also revealed a critical impact of both murine and human IgG subclasses and Fc-Fc $\gamma$ R  
101 interactions on the activities of these antibodies (Dahan et al., 2015; Liu et al., 2019).  
102 In this study, we reasoned that studying whether and how IgG subclasses and Fc-Fc $\gamma$ R  
103 interactions impact on autoantibody pathogenicity in the context of IgG4-mediated diseases can  
104 help us to understand the modes of action of IgG4 autoantibodies and disease pathogenesis. Anti-  
105 Dsg1 and ADAMTS13 autoantibodies isolated from IgG4-mediated diseases were investigated  
106 in physiologically relevant models where intact human IgG autoantibodies can interact with both  
107 their antigenic targets and Fc-receptor expressing cells.  
108


## 109 **Results**

### 110 *IgG4 is less pathogenic than IgG1 in anti-ADAMTS13 autoantibodies*

111 To directly test whether the IgG subclass of anti-ADAMTS13 autoantibodies has any impact on  
112 their pathogenicity, a pathogenic monoclonal anti-ADAMTS13 antibody (clone TTP1-420)  
113 previously isolated from TTP patient and confirmed in mice (Ostertag, Bdeir, et al., 2016;  
114 Ostertag, Kacir, et al., 2016) was expressed as either human IgG4 or IgG1 antibodies. These  
115 antibodies were confirmed to have similar binding kinetics to human ADAMTS13 (Fig. S1A).  
116 Anti-ADAMTS13 autoantibodies have been previously shown to mediate their pathogenic effect  
117 by inhibiting the enzymatic activity of ADAMTS13, which leads to an increased ultra-large form  
118 of von Willebrand factor (vWF) and platelet binding and activation (Zheng, 2015). To evaluate  
119 the pathogenicity of TTP1-420(IgG4) and TTP1-420(IgG1) autoantibodies, their impact on  
120 ADAMTS13 enzymatic activity was analyzed firstly in WT mice (Fig. 1A). As shown in Fig.  
121 1B, both TTP1-420(IgG4) and TTP1-420(IgG1)-treated WT mice displayed a significant  
122 reduction in ADAMTS13 activity soon after the treatment. However, the recovery of  
123 ADAMTS13 activity is significantly faster in TTP1-420(IgG4)-treated mice than in TTP1-  
124 420(IgG1)-treated mice, with almost complete recovery by day 8 in the former group and nearly  
125 no recovery in the latter group (Fig. 1, B and C).

126 To further evaluate the pathogenicity of TTP1-420(IgG4) and TTP1-420(IgG1) autoantibodies in  
127 the more physiologically relevant model with human Fc $\gamma$ -receptor background, Fc $\gamma$ R-humanized  
128 mice (hFCGR<sup>Tg</sup>) that recapitulate the expression profile of human Fc $\gamma$ Rs (Smith, DiLillo,  
129 Bournazos, Li, & Ravetch, 2012) were used (Fig. 1A). Consistently, TTP1-420(IgG4)  
130 autoantibodies also displayed weaker pathogenicity as compared to TTP1-420(IgG1)  
131 autoantibodies in Fc $\gamma$ R-humanized mice (Fig. 1, D and E). These results suggest that while both

132 IgG4 and IgG1 anti-ADAMTS13 autoantibodies can inhibit ADAMTS13 activity, IgG4  
 133 autoantibodies are less pathogenic as compared to IgG1 autoantibodies. Therefore, it appears that  
 134 switching to the IgG4 subclass in anti-ADAMTS13 autoantibodies represents a protective  
 135 mechanism.



136  
 137 Fig. 1. IgG4 is less pathogenic than IgG1 in anti-ADAMTS13 autoantibodies. (A) Schematic  
 138 diagram of the experimental design. In brief, wide-type C57BL/6 or hFCGR<sup>Tg</sup> mice were treated  
 139 with 10 μg of control human IgG (Ctrl hlgG, n ≥ 3), or anti-ADAMTS13 TTP1-420(IgG1) or  
 140 TTP1-420(IgG4) (n ≥ 4) on day 0 through tail vein injection, blood was collected on day -1, day  
 141 1, day 5 and day 8 and analyzed for ADAMTS13 activity. (B-E) Plots showing ADAMTS13  
 142 activity in the plasma of WT (B, C) or hFCGR<sup>Tg</sup> (D, E) mice treated with the indicated  
 143 antibodies at the indicated time points and analyzed by the FRETs-VWF73 assay, represented as  
 144 relative fluorescence units (RFU) changing rates over time (RFU/min) (B, D), and the RFU


145 change within 1 hour on day -1 and day 8 (C, E). Mean  $\pm$  SEM values are plotted. Two-way  
146 ANOVA with Tukey's (B, D) or Sidak's (C, E) multiple comparisons tests. \*  $p < 0.05$ , \*\*  $p <$   
147  $0.01$ , \*\*\*  $p < 0.001$ , \*\*\*\*  $p < 0.0001$ . A representative of two independent experiments is  
148 shown.

149

150 *Activating Fc $\gamma$ R-mediated IgG effector function enhances the pathogenicity of anti-ADAMTS13*  
151 *autoantibodies*

152 Human IgG4 and IgG1 are very different in mediating Fc $\gamma$ R-dependent effector function, with  
153 IgG4 being much less potent due to its weaker binding affinity to activating Fc $\gamma$ Rs (5, 33),  
154 including both mouse and human activating Fc $\gamma$ Rs (References (29, 33, 34) and Fig. S1B). To  
155 understand the basis of the differential pathogenicity of TTP1-420(IgG4) and TTP1-420(IgG1)  
156 autoantibodies, we investigated whether Fc-Fc $\gamma$ R interaction impacts on anti-ADAMTS13  
157 autoantibody pathogenicity using Fc $\gamma$ R-deficient mice (Fc $\gamma$ R $\alpha^{\text{null}}$ ) (Fig. 2A). As shown in Fig.  
158 2B, while TTP1-420(IgG1)-treated WT and Fc $\gamma$ R $\alpha^{\text{null}}$  mice displayed comparable levels of  
159 reduction in ADAMTS13 activity at the early time points (day 1 and day 5) (Fig. 2B), the  
160 recovery of ADAMTS13 activity is significantly faster in Fc $\gamma$ R $\alpha^{\text{null}}$  mice (Fig. 2, B and C).

161 These results suggest that while Fc $\gamma$ R-mediated function is not essential for the pathogenicity of  
162 anti-ADAMTS13 autoantibodies, it has an enhancing effect. Further investigation in Fc receptor  
163 common  $\gamma$ -chain deficient mice (*Fcer1g*<sup>-/-</sup>), which lack functional activating Fc $\gamma$ Rs, showed that  
164 *Fcer1g*<sup>-/-</sup> mice have accelerated recovery of ADAMTS13 enzyme activity (Fig. 2, A, D and E),  
165 suggesting that activating Fc $\gamma$  receptors are responsible for the enhancing effect of Fc $\gamma$ Rs to the  
166 pathogenicity of anti-ADAMTS13 autoantibodies.



167

168 Fig. 2. The protective effect of the IgG4 subclass in anti-ADAMTS13 autoantibodies is due to  
 169 reduced  $Fc\gamma R$ -mediated antibody effector function. (A) Schematic diagram of the experimental  
 170 design. In brief, WT,  $Fc\gamma R\alpha^{null}$ , or  $Fc\epsilon R1g^{-/-}$  mice were treated and analyzed as in Fig. 1A. (B-E)  
 171 Plots showing ADAMTS13 activity in the plasma of WT and  $Fc\gamma R\alpha^{null}$  mice (B, C), WT and  
 172  $Fc\epsilon R1g^{-/-}$  mice (D, E), or WT mice (F, G) treated with the indicated antibodies and analyzed at  
 173 indicated time points as in Fig. 1, B and C, represented as RFU changing rates over time

174 (RFU/min) (B, D, F), and the RFU change within 1 hour on the indicated days (C, E, G). Mean  $\pm$   
175 SEM values are plotted. Two-way ANOVA with Sidak's (B-E and G) or Tukey's (F) multiple  
176 comparisons tests. \*  $p < 0.05$ , \*\*  $p < 0.01$ , \*\*\*  $p < 0.001$ , \*\*\*\*  $p < 0.0001$ . A representative of  
177 two independent experiments is shown.


178

179 To rule out the possibility that non-Fc $\gamma$ R factors are responsible for the reduced pathogenic  
180 function of anti-ADAMTS13 autoantibodies in Fc $\gamma$ R $\alpha^{\text{null}}$  and *Fc $\gamma$ R1g<sup>-/-</sup>* mice, WT mice were  
181 treated with two variants of TTP1-420(IgG1) autoantibodies with different Fc $\gamma$ R-binding  
182 property (Fig. 2A, Table S1): 1) the N297A variant with reduced Fc $\gamma$ R-binding and effector  
183 function (Fig. S1B and references (Sazinsky et al., 2008)); 2) the GASDALIE variant with  
184 enhanced Fc $\gamma$ R-binding and effector function (Fig. S1B and References (Bournazos, DiLillo,  
185 Goff, Glass, & Ravetch, 2019)). As shown in Fig. 2F, while both TTP1-420(N297A) and TTP1-  
186 420(GASDALIE) autoantibodies induced a significant reduction in ADAMTS13 enzyme activity  
187 (Fig. 2F), TTP1-420(N297A)-treated mice recovered much faster (Fig. 2, F and G). These results  
188 suggest that while the activating Fc $\gamma$ R-mediated effector function is not absolutely required for  
189 the pathogenic function of anti-ADAMTS13 autoantibodies, it does have a critical enhancing  
190 effect, likely by depleting ADAMTS13-autoantibodies immune complex.

#### 191 *IgG4 autoantibodies deplete relatively less ADAMTS13 in acquired TTP patients*

192 To investigate whether IgG4 autoantibodies have a less depleting effect on ADAMTS13, plasma  
193 samples of a cohort of 44 acquired TTP patients were analyzed (Table S2). The majority of these  
194 samples were confirmed to contain anti-ADAMTS13 autoantibodies, with 43 out of 44 TTP  
195 samples have anti-ADAMTS13 autoantibody signal levels that are two-fold higher than healthy  
196 control (HC) average levels, which were considered as the background (Fig. 3, A and F). All

197 TTP samples were confirmed to have severely reduced ADAMTS13 activity (with all samples  
 198 have less than 5% ADAMTS13 activity) (Fig. 3B). Consistent with previous reports (Bettoni et  
 199 al., 2012; Ferrari et al., 2009), ADAMTS13 antigen levels were also reduced (Fig. 3C), and a  
 200 correlation between ADAMTS13 activity and antigen levels was observed (Fig. 3D). Further  
 201 analysis of IgG1 and IgG4 anti-ADAMTS13 autoantibodies showed that most TTP samples have  
 202 both IgG1 and IgG4 autoantibodies (Fig. 3, E and F) with an inverse correlation (Fig. 3F).



203



204 Fig. 3. ADAMTS13-specific IgG1 levels in the plasma of acquired TTP patients inversely  
205 correlate to the ADAMTS13 Ag levels and activity. (A-C) Plots showing ADAMTS13-specific  
206 IgG (A), ADAMTS13 activity (B), and ADAMTS13 antigen (C) levels in the plasma of HC (n =  
207 23) and acquired TTP patients during the acute phase (n = 44). (D) Plot showing correlation  
208 analysis of ADAMTS13 activity with ADAMTS13 Ag concentration in TTP patients. (E)  
209 ADAMTS13-specific IgG1 (left panel) and IgG4 (right panel) levels in the plasma of TTP  
210 patients and HC. (F) Plot showing correlation analysis of ADAMTS13-specific IgG1 with IgG4  
211 levels in TTP patients, with the threshold for IgG1 and IgG4 autoantibodies (two times of HC  
212 average values) annotated. (G-J) Plots showing correlation analysis between the anti-  
213 ADAMTS13 IgG1 (G, H) and IgG4 (I, J) levels with ADAMTS13 activity (G, I) and  
214 ADAMTS13 Ag (H, J) levels in TTP patients, respectively. (K) Plots showing IgG1 and IgG4  
215 anti-ADAMTS13 levels in TTP plasma samples normalized to HC, with IgG1 dominant TTP and  
216 IgG4 dominant TTP samples annotated. (L, M) Plotting showing ADAMTS13 activity (L) and  
217 antigen (M) levels in TTP plasma samples as annotated in (K). Each symbol is derived from an  
218 individual plasma sample. Mean  $\pm$  SEM values are plotted. Unpaired nonparametric Mann-  
219 Whitney test (A, B, C, E, L, M) or linear regression analysis (D, F-J). \*\*\*  $p < 0.001$ , \*\*\*\*  $p <$   
220  $0.0001$ , ns, non-significant.

221  
222 Interestingly, while IgG1 autoantibodies have a significant inverse correlation with ADAMTS13  
223 antigen and activity levels, IgG4 autoantibodies do not (Fig. 3, G to J), suggesting that IgG4  
224 autoantibodies have relatively less impact on ADAMTS13 antigen and activity levels.

225 Given the inverse correlation between IgG1 and IgG4 autoantibodies in these TTP samples, they  
226 were divided into two groups: IgG1 and IgG4 dominant TTP samples, respectively (Fig. 3K).

227 Notably, while these two groups have similar ADAMTS13 activity levels (Fig. 3L), the IgG4  
228 dominant group has significantly higher ADAMTS13 antigen levels (Fig. 3M). These results  
229 suggest that IgG4 anti-ADAMTS13 autoantibodies confer relatively less ADAMTS13 depletion.

230 *IgG4 and IgG1 anti-Dsg1 autoantibodies have shared binding epitopes and different abundance*  
231 *in PF patients*

232 Previously, it has been described that the IgG1 anti-Dsg1 autoantibodies are observed in both  
233 healthy subjects and endemic PF patients, and the accumulation of IgG4 anti-Dsg1  
234 autoantibodies is a key step in the development of the disease (Warren et al., 2003). At the same  
235 time, the binding epitope of anti-Dsg1 autoantibodies is critical for the pathogenicity of anti-  
236 Dsg1 autoantibodies (Li et al., 2003), raising the possibility that IgG4 and IgG1 anti-Dsg1  
237 autoantibodies bind to different Dsg1 epitopes (Aoki et al., 2015). To investigate whether the  
238 binding epitope represents a major difference between IgG1 and IgG4 anti-Dsg1 autoantibodies,  
239 serum samples of a cohort of 53 PF patients admitted to Rui Jin Hospital, Shanghai, China, were  
240 analyzed for the total levels and subclasses of IgG anti-Dsg1 autoantibodies (Table S3).  
241 Consistent with previous studies (Warren et al., 2003), PF patients have both IgG4 and IgG1  
242 anti-Dsg1 autoantibodies (Fig. 4A). However, IgG4 autoantibodies are much more abundant than  
243 IgG1 autoantibodies (Fig. 4A, and Fig. S2A). Based on the clinical symptoms and medication,  
244 these PF patients were assigned to the "stable" and "active" groups. Both groups have more IgG4  
245 autoantibodies than IgG1 autoantibodies (Fig. S2A). The "active" PF samples have higher  
246 autoantibody levels as compared to the "stable" PF samples, regardless of what IgG subclasses  
247 were considered (Fig. S2A).  
248 The binding epitopes of IgG4 and IgG1 anti-Dsg1 autoantibodies were analyzed based on their  
249 binding to a series of Dsg1/Dsg2 chimeric proteins containing different Dsg1 extracellular

250 domains (Fig. S2B). Interestingly, all the tested samples with significant IgG1 antibodies showed  
251 that their IgG1 and IgG4 anti-Dsg1 autoantibodies have the same chimeric antigen-binding  
252 profiles (Fig. 4B). These results suggest that IgG1 and IgG4 anti-Dsg1 autoantibodies have  
253 different abundance but shared binding epitopes, at least in the patient samples analyzed in our  
254 study, and that the IgG subclass of these anti-Dsg1 autoantibodies could be a key variable in PF  
255 pathogenesis.

256 *IgG4 is not less, if not more, pathogenic than IgG1 in anti-Dsg1 autoantibodies*

257 To investigate the impact of IgG4 subclass on the pathogenicity of anti-Dsg1 autoantibodies, we  
258 studied anti-Dsg1 autoantibodies previously isolated from PF patients and proven to be  
259 pathogenic in both neonatal mouse and human tissue-culture models (Ishii et al., 2008;  
260 Yamagami et al., 2009). Two anti-Dsg1 antibody clones (PF1-8-15 and PF24-9) were produced  
261 as IgG1 and IgG4 antibodies and confirmed to bind to Dsg1 with similar kinetics (Fig. S3A).  
262 When tested in neonatal mice, both human IgG4 and IgG1 anti-Dsg1 antibodies induced  
263 epidermal acantholysis (Fig. S3B).

264 Since pemphigus is a chronic disease that often affects adults and older adults in the context of  
265 ongoing immune responses (Schmidt, Kasperkiewicz, & Joly, 2019), and the neonatal mouse  
266 model is limited by the short time (usually for a few hours) allowed for investigation and its  
267 underdeveloped immune system, we developed a PF model based on adult mice. As shown in  
268 Fig. S4A, adult hFCGR<sup>Tg</sup> mice treated with PF24-9(IgG1) autoantibodies could reproduce the  
269 clinical, histological and immunological features of PF patients, including erosions that heal with  
270 crusting and scaling, intercellular deposition of human IgG in the epidermis at prelesion and  
271 lesion sites, and histopathological changes including ear and skin epidermal blistering formation.  
272 In addition, we observed the thickened epidermis and leukocyte infiltration at the lesion sites


273 during the disease onset (Fig. S4A), which generally last for a few days depending on the amount  
274 of autoantibody administered. These observations are consistent with previous analysis of skin  
275 samples of pemphigus patients (Furtado, 1959; Rados, 2011) and the recent description of  
276 lymphocyte infiltration at the lesion sites in patients (Yuan et al., 2017; Zhou et al., 2019).  
277 Therefore, the adoptive transfer of anti-Dsg1 antibodies is sufficient to initiate pemphigus in  
278 adult mice, in which the pathogenicity of anti-Dsg1 autoantibodies can be studied in the process  
279 of disease onset and resolution and in the context of an intact immune system.

280 To investigate whether IgG subclass impacts on the pathogenicity of anti-Dsg1 autoantibodies,  
281 the pathogenicity of high dosage of PF24-9(IgG4) and PF24-9(IgG1) autoantibodies was  
282 evaluated in hFCGR<sup>Tg</sup> mice (Fig. S4B). When skin and ear tissues were analyzed, epidermal  
283 blistering and leukocyte infiltration were observed in both PF24-9(IgG4) and PF24-9(IgG1)  
284 autoantibody-treated mice (Fig. S4C). Interestingly, when the anti-Dsg1 autoantibody dosage is  
285 reduced, it appears that PF24-9(IgG4) is not less, but tends to be more pathogenic than PF24-  
286 9(IgG1) antibodies based on the histopathological symptoms (Fig. 4C), in contrast with our  
287 analysis of anti-ADAMTS13 autoantibodies.

#### 288 *Anti-Dsg1 autoantibodies are more pathogenic in the absence of FcγRs*

289 To investigate whether Fc-FcγR interaction impacts on the pathogenicity of anti-Dsg1  
290 antibodies, FcγRα<sup>null</sup> mice were used. Strikingly, both PF24-9(IgG4) and PF24-9(IgG1)  
291 autoantibodies induced more severe ear lesions in FcγRα<sup>null</sup> mice than in hFCGR<sup>Tg</sup> mice (Fig.  
292 4C). Increased infiltration of myeloid effector cells (Fig. S5, A to C), especially inflammation-  
293 relevant neutrophils (Fig. 4, D to F), was observed in the ears of FcγRα<sup>null</sup> mice treated with  
294 either PF24-9(IgG4) or PF24-9(IgG1) autoantibodies. While these results suggest that anti-Dsg1

295 autoantibodies induced acute inflammation together with skin lesions, they also suggest an FcγR-  
 296 mediated mechanism in attenuating anti-Dsg1 autoantibodies-induced skin lesions.



297

298 Fig. 4. IgG4 is not less, if not more, pathogenic than IgG1 in Dsg1 autoantibodies, and both  
 299 could be exacerbated by FcγRs deficiency. (A) Plots showing the Unit values of indicated Dsg1-  
 300 specific antibodies in the serum of PF patients (n = 53). (B) Plots showing the levels of IgG1 and


301 IgG4 antibodies in two PF patients that bind to Dsg1, Dsg2, or Dsg1/Dsg2 chimeric molecules  
302 containing the indicated Dsg1 EC domains. (C) Representative photos showing the HE staining  
303 results of ears of hFCGR<sup>Tg</sup> and FcγRα<sup>null</sup> mice 3 days after being treated with 0.4 mg of Ctrl  
304 hIgG (n = 3), or PF24-9(IgG1) or PF24-9(IgG4) (n ≥ 4) through tail vein injection. Scale bars:  
305 200 μm. (D-F) Representative flow cytometry profiles (D) and plots showing the percentage (E)  
306 and cell number (F) of infiltrating neutrophils (CD11b<sup>+</sup>Gr1<sup>hi</sup>) among leukocytes (CD45<sup>+</sup>) in the  
307 ears of mice in (C). Each symbol is derived from an individual PF patient (A) or an individual  
308 mouse (E, F). Mean ± SEM values are plotted (A, E, F). One-way ANOVA (A) and Two-way  
309 ANOVA (E, F) with Tukey's multiple comparisons test. \*  $p < 0.05$ , \*\*  $p < 0.01$ , \*\*\*\*  $p <$   
310 0.0001. A representative of two independent experiments is shown.

311

### 312 *Anti-Dsg1 autoantibodies with low affinity to FcγRs are more pathogenic*

313 To further investigate whether Fc-FcγR interactions attenuate anti-Dsg1 autoantibody  
314 pathogenicity, the N297A and GASDALIE variants (with reduced FcγR binding and enhanced  
315 activating FcγR binding, respectively; references (Bournazos et al., 2019; Sazinsky et al., 2008))  
316 of IgG1 anti-Dsg1 autoantibodies were produced (Fig. S3A) and evaluated in the adult  
317 pemphigus model. Strikingly, the N297A variants of both pathogenic anti-Dsg1 clones (PF1-8-  
318 15 and PF24-9) are much more potent than their matched GASDALIE variants in inducing ear  
319 lesions (Fig. 5A, and Fig. S6, A and B) and inflammation in hFCGR<sup>Tg</sup> mice, as shown by  
320 increased ear thickness and weight (Fig. 5, B and C, and Fig. S6, C and D), as well as increased  
321 infiltration neutrophils (Fig. 5, D and E, Fig. S6, E to G). Histopathological analysis of skin  
322 lesions at an early time point (day 3) (Fig. S6A) and a later time point (day 6) (Fig. S6B)  
323 revealed that while both the PF1-8-15(N297A) and PF1-8-15(GASDALIE) variants could induce





324

325 Fig. 5. Anti-Dsg1 autoantibodies with reduced Fc $\gamma$ R-binding are more pathogenic. (A)  
 326 Representative photos showing the HE staining results of ears of hFCGR<sup>Tg</sup> mice 3 days after  
 327 being treated with 0.5 mg of Ctrl hIgG (n = 3), or PF24-9(N297A) or PF24-9(GASDALIE)  
 328 autoantibodies (n = 5). Scale bars: 200  $\mu$ m. (B, C) Ear thickness (B) and weight (C) of hFCGR<sup>Tg</sup>  
 329 mice in (A) when sacrificed at day 3. (D, E) Plots showing the percentage (D) and cell number  
 330 (E) of infiltrating neutrophils (CD11b<sup>+</sup>Gr1<sup>hi</sup>) among leukocytes (CD45<sup>+</sup>) in the ears of mice in  
 331 (A). (F) Photos of nude mice 2 days after being treated with 0.4 mg of Ctrl hIgG or PF1-8-  
 332 15(N297A) or PF1-8-15(GASDALIE) antibodies (n = 5). Each symbol is derived from an

333 individual mouse. Mean  $\pm$  SEM values are plotted. One-way ANOVA with Tukey's multiple  
334 comparisons test (C-E). \*  $p < 0.05$ , \*\*  $p < 0.01$ .

335


336 skin lesions, the PF1-8-15(GASDALIE) variant-treated mice recovered faster. The pathogenic  
337 function of N297A and GASDALIE anti-Dsg1 autoantibodies was also evaluated in nude mice,  
338 where skin lesions can be better observed. As shown in Fig. 5F and Fig. S6I, PF1-8-15(N297A)  
339 autoantibodies induced more severe skin lesions and slower recovery as compared to matched  
340 PF1-8-15(GASDALIE) autoantibodies. These results further support the notion that Fc-Fc $\gamma$ R  
341 interaction attenuates the pathogenicity of anti-Dsg1 autoantibodies, and that this process is  
342 independent of T cells. Consistently, the PF1-8-15(GASDALIE) autoantibody also induced more  
343 severe skin lesions and inflammation, as well as increased infiltrating neutrophils in Fc $\gamma$ R $\alpha^{\text{null}}$   
344 mice as compared in hFCGR<sup>Tg</sup> mice (Fig. S7, A to E).

345 *Fc $\gamma$ R-mediated effector function promotes the clearance of immune complexes and dead*  
346 *keratinocytes induced by anti-Dsg1 autoantibodies*

347 Since both Fc $\gamma$ R-null (N297A) and Fc $\gamma$ R-enhanced (GASDALIE) anti-Dsg1 autoantibodies can  
348 trigger skin lesions, we reasoned that the observed exacerbation of skin lesions associated with  
349 reduced Fc-Fc $\gamma$ R binding is due to the impact of Fc $\gamma$ R-mediated effector function at the tissue  
350 repair stage (Gaipf et al., 2006; Nagata, 2018). Analysis of the levels of remaining anti-Dsg1  
351 autoantibodies in the serum of both hFCGR<sup>Tg</sup> and nude mice showed that in the presence of  
352 Fc $\gamma$ Rs, GASDALIE anti-Dsg1 autoantibodies are depleted faster than N297A anti-Dsg1  
353 autoantibodies, suggesting more Fc $\gamma$ R-dependent uptake of Dsg1-autoantibodies immune  
354 complexes (Fig. 6, A and B, and Fig. S6H). Consistently, the levels of Dsg1-autoantigen-  
355 autoantibody immune complexes were higher in PF1-8-15(N297A)-treated mice than in PF1-8-



356 15(GASDALIE)-treated mice (Fig. 6C). Notably, we also observed more dead keratinocytes at  
357 skin lesions in PF1-8-15(N297A)-treated nude mice (Fig. 6D), suggesting that Fc $\gamma$ R-mediated  
358 effector function promotes the clearance of dead keratinocytes.




359  
360 Fig. 6. Fc $\gamma$ R-mediated effector function promotes the clearance of immune complexes and dead  
361 keratinocytes induced by anti-Dsg1 autoantibodies. (A-C) Plots showing the levels of serum  
362 remaining free hIgG (A, B) and Dsg1-Ab immune complex (C) in mice as treated in Fig. 5A (A),  
363 or in nude mice 2 days after being treated with 0.4 mg of anti-Dsg1 IgG1 variants PF1-8-  
364 15(N297A) or PF1-8-15(GASDALIE) (B, C). (D) Photos showing the TUNEL staining results of  
365 skin tissues collected from mice in (B-C), with positive cells (green) correspond to the epidermis.  
366 Scale bars: 100  $\mu$ m (D). Each photo or symbol is derived from an individual mouse. Mean  $\pm$   
367 SEM values are plotted. One-way ANOVA with Tukey's multiple comparisons (A, B, C). \*\*\*\*  $p$   
368 < 0.0001.

369

370 *FcγR-enhanced non-pathogenic anti-Dsg1 autoantibodies attenuate skin lesions induced by*  
371 *pathogenic anti-Dsg1 antibodies*

372 We further hypothesized that non-pathogenic anti-Dsg1 antibodies could also promote the FcγR-  
373 mediated clearance of autoantigen-autoantibody immune complexes and, therefore, the healing  
374 of skin lesions. To test this hypothesis, a non-pathogenic but cross-reactive anti-Dsg1  
375 autoantibody clone (PF1-2-22) previously isolated from PF patients (Yamagami et al., 2009),  
376 was produced as the GASDALIE variant and confirmed to have different binding epitope as  
377 pathogenic anti-Dsg1 clones PF1-8-15 and PF24-9 (Fig. S3C, Table S4). Notably, the non-  
378 pathogenic PF1-2-22(GASDALIE) could attenuate the skin lesions induced by pathogenic PF1-  
379 8-15(N297A) autoantibodies in nude mice, as shown by the reduced skin lesions (Fig. 7, A and  
380 B) and epidermal blistering (Fig. 7C). Furthermore, fewer apoptotic keratinocytes in the  
381 epidermis were observed in skin tissues isolated from non-pathogenic anti-Dsg1 autoantibody-  
382 treated mice (Fig. 7D). These results suggest that the FcγR-mediated effector function can  
383 attenuate pathogenic anti-Dsg1 autoantibody-induced skin lesions by promoting the clearance of  
384 apoptotic keratinocytes that may otherwise undergo secondary necrosis and induce  
385 inflammation, and therefore contribute to the healing of Dsg1 autoantibody-induced skin lesions  
386 in pemphigus foliaceus models.



387

388 Fig. 7. FcγR-enhanced non-pathogenic anti-Dsg1 autoantibodies attenuate skin lesions induced  
389 by pathogenic anti-Dsg1 antibodies. (A) Schematic diagram of the experimental design for  
390 evaluating the impact of non-pathogenic anti-Dsg1 IgG1 with GASDALIE mutations (PF1-2-  
391 22(GASDALIE)) on the pathogenicity of pathogenic anti-Dsg1 IgG1 with N297A mutation  
392 (PF1-8-15(N297A)) in nude mice. (B-D) Photos showing skin lesions around the mouth (B), HE

393 staining results of skin tissues (C), TUNEL staining results of skin (D) in nude mice 2 days after  
394 being treated with 0.5 (B) or 0.4 mg (C, D) of pathogenic PF1-8-15(N297A) together with (+) or  
395 without (-) an equal amount of non-pathogenic (PF1-2-22(GASDALIE)) antibodies, with  
396 TUNEL positive cells (green) correspond to the epidermis in (H). Scale bars: 200  $\mu\text{m}$  (C) or 100  
397  $\mu\text{m}$  (D). Each photo is derived from an individual mouse.  
398

## 399 Discussion

400 It is striking that the IgG4 subclass and Fc-Fc $\gamma$ R interaction have the opposite impact on the  
401 pathogenicity of autoantibodies isolated from different IgG4-mediated autoimmune diseases.  
402 Although the IgG4 autoantibodies are pathogenic in both the TTP and PF patients and animal  
403 models, the IgG4 subclass can attenuate the pathogenic function of anti-ADAMTS13  
404 autoantibodies when the otherwise more pathogenic IgG1 subclass is considered. This is due, at  
405 least in part, to its weak Fc $\gamma$ R-mediated effector function since either reducing Fc $\gamma$ R binding  
406 affinity or ablating Fc $\gamma$ Rs can also attenuate the pathogenicity of anti-ADAMTS13  
407 autoantibodies. In contrast, the IgG4 subclass and Fc-Fc $\gamma$ R interaction have the opposite impact  
408 on the pathogenic function of anti-Dsg1 autoantibodies, since either reducing Fc $\gamma$ R binding  
409 affinity or ablating Fc $\gamma$ Rs can exacerbate their pathogenic function. Our results provide direct  
410 evidence for the differential impact of IgG subclasses on the pathogenic function of  
411 autoantibodies.

412 Previously, mixed results have been reported regarding the pathogenic potential of IgG1 and  
413 IgG4 autoantibodies in both TTP and PF. On the one hand, IgG4 autoantibody-dominant TTP  
414 serum samples were recently reported to have a stronger inhibitory effect on ADAMTS13  
415 activity than IgG1 autoantibody-dominant TTP serum samples (Sinkovits et al., 2018), despite  
416 that this difference does not seem to correlate with disease course in the same study (Sinkovits et  
417 al., 2018). On the other hand, patients with high levels of IgG1 and low levels of IgG4 anti-  
418 ADAMTS13 autoantibodies were reported to have high mortality rate (Ferrari et al., 2009); and  
419 IgG1 and IgG3, not IgG4 anti-ADAMTS13 autoantibody titers were among the most strongly  
420 associated factors with clinical severity of acute TTP (Bettoni et al., 2012). Furthermore, a  
421 subclass switching from IgG1 to IgG4, but not IgG4 to IgG1 in anti-ADAMTS13 autoantibodies

422 was observed at the first episode/remission transition in TTP (Sinkovits et al., 2018). While these  
423 studies established a correlation between IgG subclass and disease severity, a direct comparison  
424 between IgG4 and IgG1 autoantibodies has not been allowed given the complexity of polyclonal  
425 anti-ADAMTS13 autoantibodies in serological studies. The majority of these studies supported  
426 our conclusion that IgG4 is less pathogenic as compared to matched IgG1 anti-ADAMTS13  
427 autoantibodies. Also, consistently, the inverse correlation between IgG4 and IgG1 anti-  
428 ADAMTS13 autoantibodies and their association with different levels of ADAMTS13 antigen  
429 levels have been described previously in an independent study (Ferrari et al., 2009).

430 Regarding the impact of IgG subclass on autoantibody pathogenicity in PF, it has been clear that  
431 the emergence of IgG4 anti-Dsg1 autoantibodies has a stronger correlation than IgG1  
432 autoantibodies with endemic PF disease activity (Warren et al., 2003). Previously, Fab fragments  
433 of anti-Dsg1 antibodies were reported to be more pathogenic as compared to intact IgG4  
434 autoantibodies (Rock et al., 1990). While it suggests that the IgG Fc is not essential for anti-Dsg1  
435 autoantibody pathogenicity, it also supports a role of IgG4 Fc in modulating the pathogenicity of  
436 anti-Dsg1 autoantibodies. Interestingly, "non-pathogenic IgG1 anti-Dsg1 antibodies" described  
437 in endemic PF patients in the preclinical stage and healthy controls living in the endemic areas  
438 were proposed to have non-pathogenic binding epitopes (Aoki et al., 2015; Li et al., 2003) and  
439 no functional roles, as far as we know, have been proposed for the IgG1 subclass and these "non-  
440 pathogenic antibodies". Our study provides direct evidence supporting a role of the IgG subclass  
441 and Fc-FcγR interaction in the pathogenic function of anti-Dsg1 autoantibodies isolated from PF  
442 patients, as well as a potentially protective role of non-pathogenic IgG1 anti-Dsg1 antibodies  
443 described previously.



444 The opposite impact of the IgG4 subclass and Fc-Fc $\gamma$ R interaction on the pathogenic function of  
445 autoantibodies in anti-ADAMTS13 and anti-Dsg1 autoantibodies suggests that these  
446 autoantibodies have different modes of action in IgG4-mediated autoimmune diseases.  
447 Previously, many antibodies have been studied for their mode of action and the impact of Fc-  
448 Fc $\gamma$ R engagement. Interestingly, different types of antibodies categorized by mode of action are  
449 impacted very differently by Fc-Fc $\gamma$ R engagement. It has been well-established that effector  
450 antibodies, which eliminate their targets (bacteria, virus, toxin, cancer cells et al.), all require  
451 activating Fc $\gamma$ Rs to mediated their optimal activities (reviewed in (Bournazos & Ravetch, 2017)).  
452 Agonistic antibodies targeting a number of TNF receptor superfamily members (CD40, DR5,  
453 CD137, et al.) have been shown to depend on inhibitory Fc $\gamma$ RIIB for their optimal activities  
454 (reviewed in (Beers, Glennie, & White, 2016)). In contrast, anti-PD1 antibodies that function by  
455 blocking PD1/PD-L1 interaction have been shown to function best when they do not bind to  
456 Fc $\gamma$ Rs (Dahan et al., 2015). While these findings are important for the design and engineering or  
457 antibody applications according to their modes of action, it has not been well-studied whether  
458 they apply to autoantibodies, with many of which have unclear modes of action.

459 Our study of anti-ADAMTS13 autoantibodies suggests that they have multiple functional  
460 mechanisms. On the one hand, their enzyme inhibition ability in the absence of Fc $\gamma$ Rs suggests  
461 that anti-ADAMTS13 antibodies can function by blocking, which is consistent with their  
462 requirement of specific binding epitopes — autoantibodies targeting the spacer domain and  
463 metalloprotease domain of ADAMTS13, which are required for binding to and cleaving its  
464 substrate vWF, have been reported to be pathogenic (Feys et al., 2010; Ostertag, Bdeir, et al.,  
465 2016; Ostertag, Kacir, et al., 2016; Zheng, 2015). On the other hand, the protective effect of the  
466 IgG4 subclass (versus IgG1) and Fc $\gamma$ R-deficiency in our TTP model suggest that anti-

467 ADAMTS13 autoantibodies also function at least in part as effector antibody. Since  
468 ADAMTS13 proteins are circulating in the blood, a plausible mechanism would be Fc $\gamma$ R-  
469 mediated depletion of ADAMTS13 can further exacerbate the reduction of ADAMTS13  
470 enzymatic activities. This notion is supported by the observation that IgG4-ADAMTS13 immune  
471 complexes persist longer than IgG1-ADAMTS13 immune complexes, likely due to reduced  
472 clearance (Ferrari et al., 2014). In this regard, it is noted that among all the natural human IgG  
473 subclasses, IgG4 has the least effector function, suggesting that switching to the IgG4 subclass is  
474 a protective mechanism in the context of TTP.

475 The increased pathogenic function of anti-Dsg1 autoantibodies observed in Fc $\gamma$ R-deficient mice  
476 (vs. Fc $\gamma$ R-sufficient mice) and in the form of IgG variants with weak binding affinity to Fc $\gamma$ Rs  
477 (vs. IgG variants with enhanced binding affinity to Fc $\gamma$ Rs) suggest that anti-Dsg1 autoantibodies  
478 also primarily function as blocking antibodies (Koneczny, 2018). This is also supported by the  
479 previous finding that these antibodies require specific binding epitope, and they can function in  
480 the form of scFv (Ishii et al., 2008; Yamagami et al., 2009; Yoshida et al., 2017). However, it is  
481 intriguing that Fc-Fc $\gamma$ R interaction attenuates anti-Dsg1 autoantibody-induced pathogenicity,  
482 which suggests that either Fc $\gamma$ R-dependent effector function or agonistic function has a  
483 contribution to the overall effect of anti-Dsg1 autoantibodies. The agonistic function is not likely  
484 given that Dsg1-signaling has been suggested to be a pathogenic mechanism (Hammers &  
485 Stanley, 2020; Spindler et al., 2018). Since anti-Dsg1 autoantibody-induced skin lesions belong  
486 to the type II hypersensitivity, in which the keratinocytes are attacked and inefficiently clearance  
487 of apoptotic cells may trigger secondary necrosis and delay the healing, our results support that  
488 Fc $\gamma$ R-mediated effector function is beneficial for tissue repair and wound healing by contributing  
489 to the clearance of Dsg1-autoantibody immune complexes. It will be interesting to investigate



490 whether other autoantibodies are also involved in the clearance of autoantigen and cell debris  
491 containing autoantigens.

492 While our study of anti-ADAMTS13 autoantibodies supports the notion that switching to  
493 immune-inert IgG4 subclass is a protective mechanism in IgG4-mediated autoimmune diseases,  
494 our analysis of anti-Dsg1 autoantibodies suggests the opposite. It appears that the distinct impact  
495 of IgG subclass and Fc-Fc $\gamma$ R engagement on different antibodies with blocking function lies in  
496 the effect of their effector functions in their respective context. In the previously described  
497 blocking anti-PD1 antibodies (Dahan et al., 2015), either Fc $\gamma$ R-dependent depletion of PD1-  
498 expressing T cells or agonistic function of anti-PD1 antibodies results in the reduction of T cell  
499 immunity, which counters the effect of blocking PD1 signal in T cells. In the case of anti-  
500 ADAMTS13 autoantibodies, Fc $\gamma$ R-mediated depletion of ADAMTS13 synergizes with the  
501 blocking function of anti-ADAMTS13 autoantibodies to further reduce the enzymatic activity of  
502 ADAMTS13. In the case of anti-Dsg1 autoantibodies, the Fc $\gamma$ R-mediated effector function may  
503 indirectly counter the pathogenic function of anti-Dsg1 autoantibodies by promoting the  
504 clearance of apoptotic cells containing autoantigens and tissue repair. Therefore, carefully  
505 examining the impact of IgG subclasses and Fc-Fc $\gamma$ R interactions on autoantibody functions is  
506 critical for understanding their mode of action in the context of different biological processes and  
507 disease settings.

508

## 509 **Materials and Methods**

### 510 **Patients and samples collection**

511 We analyzed plasma samples of 44 acquired TTP patients investigated in Jiangsu Institute of  
512 Hematology, The First Affiliated Hospital of Soochow University, Jiangsu, China, between  
513 September 2019 and April 2020. This institute is providing diagnostic services for patients in  
514 China suspected of having thrombotic microangiopathies. The diagnosis of acquired TTP was  
515 based on the following criteria: (1) thrombocytopenia (platelet count below 150 G/L) and  
516 hemolytic anemia (Coombs-negative anemia, elevated LDH); (2) deficient ADAMTS13 activity  
517 (< 5%, measured by R-CBA assay (the residual collagen-binding activity), as described below);  
518 and (3) detectable inhibitory anti-ADAMTS13 autoantibodies as analyzed by the R-CBA method  
519 (Gerritsen, Turecek, Schwarz, Lammle, & Furlan, 1999). Blood samples were collected during  
520 an acute episode and anticoagulated with sodium citrate before plasma exchange therapy. Plasma  
521 samples were separated by centrifugation and stored at  $-70^{\circ}\text{C}$  until measurements. Sodium  
522 citrate-anticoagulated plasma samples were used for the determinations of ADAMTS13 activity,  
523 ADAMTS13 Ag levels and autoantibody subclasses and concentrations.

524 To study the impact of IgG subclass on the pathogenicity of anti-Dsg1 autoantibodies, 53 PF  
525 patients, including 21 patients at stable stage (defined as no new skin lesions and erosions for at  
526 least 1 month, and with gradually reducing corticosteroid dosage) and 32 patients at active stage  
527 (including newly diagnosed patients without any treatment or stable patients developing new  
528 lesions, lasting more than one week), from Department of Dermatology, Rui Jin Hospital,  
529 Shanghai Jiao Tong University School of Medicine, China, were recruited and analyzed. All PF  
530 patients exclusively had anti-Dsg1 autoantibodies, but not anti-Dsg3 autoantibodies, as detected

531 by ELISA. Serum and sodium citrate-anticoagulated plasma of healthy people was obtained from  
532 the medical center or healthy blood donors.

### 533 **Mice**

534 Adult and neonatal C57BL/6 WT mice and Balb/c nude mice were obtained from SLAC  
535 (Shanghai, China). FcγR-deficient mouse (FcγRα<sup>null</sup>) (Smith et al., 2012), FcγR-humanized  
536 mouse (FcγRα<sup>-</sup>/hFcγRI<sup>+</sup>/hFcγRIIA<sup>R131+</sup>/hFcγRIIB<sup>+</sup>/hFcγRIIIA<sup>F158+</sup>/hFcγRIIIB<sup>+</sup>, shorted for  
537 "hFCGR<sup>Tg</sup>") (Smith et al., 2012), and Fc receptor common γ-chain deficient mouse (*Fcer1g*<sup>-/-</sup>)  
538 (Clynes, Takechi, Moroi, Houghton, & Ravetch, 1998; Takai, Li, Sylvestre, Clynes, & Ravetch,  
539 1994) have been described elsewhere and were kindly provided by Dr. Jeffrey Ravetch (The  
540 Rockefeller University). hFCGR<sup>Tg</sup> or FcγRα<sup>null</sup> mice produced by breeding or by bone marrow  
541 reconstitution were used. The method to generate bone marrow chimeric mice has been  
542 described previously (Liu et al., 2019). Briefly, 8-10 weeks female C57BL/6 WT mice (SLAC,  
543 Shanghai, China) were lethally irradiated with 8 Gy X-ray using RS 2000pro X-ray biological  
544 Irradiator (Rad Source Technologies, Inc., U.S.A.), and 2 x 10<sup>6</sup> bone marrow cells of hFCGR<sup>Tg</sup>  
545 or FcγRα<sup>null</sup> mice were transferred to these irradiated mice through tail vein injection. Successful  
546 bone marrow reconstitution was confirmed two months later by analyzing FcγRIIB expression in  
547 B cells and CD11b<sup>+</sup> myeloid cells in peripheral blood by flow cytometry. Mice were used at the  
548 age of 8-12 w or 2-4 months after bone marrow reconstruction used unless stated otherwise.

### 549 **Antibodies**

550 The amino acid sequences of the variable region of TTP1-420 anti-ADAMTS13 autoantibody  
551 were obtained from a published paper (Ostertag, Kacir, et al., 2016). Nucleic acid sequences of  
552 the variable region of pathogenic PF1-8-15 and PF24-9 anti-Dsg1 scFv and non-pathogenic PF1-  
553 2-22 anti-Dsg1 scFv were obtained from the patent (Patent No.: US8846867B2). Antibody heavy

554 chain variable sequences and light chain sequences were synthesized and inserted into the  
555 pFL\_DEC expression vector with or without human IgG constant region (IgG1 or IgG4),  
556 respectively, as described previously (Liu et al., 2019). IgG1 Fc variants with specific mutations  
557 (N297A or G236A/S239D/A330L/I332E) were generated by site-directed mutagenesis. Paired  
558 antibody heavy and light chain expression vectors were used to transiently co-transfect HEK293  
559 cells. IgG antibodies in the supernatant were collected several days later and purified with  
560 protein G Sepharose (GE Healthcare), and dialyzed to PBS and stored at 4°C. LPS (endotoxin)  
561 levels were analyzed by the Limulus amoebocyte lysate assay (Thermo Scientific) and confirmed  
562 to be < 0.01 EU/μg.

### 563 **Production of hDsg1 and hDsg2 extracellular domains and their chimeric proteins**

564 DNA fragments encoding the signal peptide, pro-sequence and entire extracellular domains of  
565 Dsg1 (GenBank accession no. NM\_001942) and Dsg2 (GenBank accession no. NM\_001943)  
566 were obtained by reverse transcription-polymerase chain reaction (RT-PCR, Thermo)  
567 amplification using RNA extracted from healthy human skin (obtained from plastic surgery) by  
568 TRIzol reagent (Invitrogen) as the template. DNA fragments encoding of Dsg1/Dsg2 chimeric  
569 proteins consisting of various extracellular domain segments of Dsg1 were obtained by  
570 overlapping PCR using Dsg1 and Dsg2 vectors as the templates. The forward and reverse  
571 primers used are listed in Table S5. BamH1 and Sal1 are added to 5' and 3' end primers,  
572 respectively, and were used for subcloning the DNA fragments encoding of Dsg1/Dsg2 chimeric  
573 proteins into the pFastBac1 vector that was engineered to contain the FlagHis tag  
574 (dykdddkfvehhhhhhhh) sequence between the Sal1 and Not1 sites. The recombinant donor  
575 plasmid was used to transform competent DH10Bac<sup>TM</sup> *E. coli* cells, after which blue-white  
576 plaque assay was performed to confirm successful site-specific transposition. Dsg1, Dsg2, and

577 Dsg1/Dsg2 chimeric proteins were expressed in the Sf9 cells and purified as previously  
578 described (Ding, Diaz, Fairley, Giudice, & Liu, 1999).

## 579 **ELISA**

580 To measure the binding ability of human IgG and Fc variants to mouse FcγRs, a previously  
581 described protocol (Liu et al., 2019) was modified. Briefly, 100 μl of 2 μg/ml TTP1-420 anti-  
582 ADAMTS13 antibodies with various constant domains (IgG1/IgG4/N297A/GASDALIE) were  
583 coated in 96-well MaxiSorp™ flat plate (Nunc) at 4°C overnight. After discarding the liquid and  
584 washing with PBS containing 0.05% Tween-20 (PBST), the plates were blocked with 200 μl of 1  
585 or 2% BSA at room temperature for 2 h and washed 2 times with PBST, after which 100 μl of  
586 serially diluted (0.001-1 μg/ml, 1:3.16) biotinylated mouse FcγRs (Sino Biological) were added  
587 and incubated at RT for 1 h. Plates were then washed 3 times with PBST and further incubated  
588 with 100 μl of diluted Streptavidin-HRP (1:1000, BD Pharmingen™) for 1 h, and followed by  
589 washing four times and developing with 100 μl of TMB peroxidase substrate (KPL). The  
590 absorbance at 650 nm was recorded using a multifunctional microplate reader (SpectraMax®i3,  
591 Molecular Devices).

592 Similar protocols were applied to other ELISA analyses with except that when Dsg1, Dsg2, or  
593 Dsg1/2 chimeric proteins were involved, all reagents were dissolved or diluted in TBS-Ca buffer  
594 (TBS buffer with 1 mM CaCl<sub>2</sub>) and TBS-Ca-T (TBS-Ca containing 0.05% Tween-20) was used  
595 as washing buffer, as well as the following:

596 1) To detect the binding kinetics of TTP1-420 anti-ADAMTS13 or PF1-8-15 anti-Dsg1  
597 antibodies with different constant domains (IgG1/IgG4/N297A/GASDALIE) to their antigens,  
598 respectively, ADAMTS13 (R&D Systems, diluted with bicarbonate/carbonate buffer containing  
599 15 mM Na<sub>2</sub>CO<sub>3</sub> and 35 mM NaHCO<sub>3</sub>, pH = 9.6) and recombinant Dsg1 was coated. Serially

600 diluted specific and Ctrl hIgG (Jackson ImmunoResearch Laboratories) (0.00316-3.16 µg/ml)  
601 were analyzed; TTP1-420(IgG1) was used as irrelevant IgG1 control for anti-Dsg1 antibodies.  
602 Biotinylated mouse anti-human lambda chain (1:2000, Clone JDC-12 (RUO), BD  
603 Pharmingen™) was used as detecting antibody.

604 2) To compare the binding epitopes of different anti-Dsg1 antibody clones, different anti-Dsg1  
605 IgG1 antibody clones (PF1-8-15, PF24-9, or PF1-2-22) or TBS-Ca as negative control were  
606 coated; recombinant Dsg1 (1 µg/ml) was analyzed; biotinylated PF1-8-15(IgG1) (1 µg/ml), or  
607 αCD40(IgG1) (1 µg/ml, as negative control) (EZ-Link® Micro Sulfo-NHS-Biotinylation Kit  
608 (Thermo scientific)) was used as detecting antibody.

609 3) To determine the total IgG, IgG1, and IgG4 anti-ADAMTS13 antibodies in TTP and HC  
610 plasma samples, ADAMTS13 was coated; sodium citrate-anticoagulated plasma (dilution: 1 to  
611 100 for IgG, 1 to 10 for IgG1 and IgG4) were analyzed; serially-diluted TTP1-420(IgG1) and  
612 TTP1-420(IgG4) antibodies were used as standards of IgG1 and IgG4, respectively; HRP-  
613 conjugated goat anti-human IgG Fc (1:10000, Bethyl Laboratories), mouse anti-human IgG1  
614 (1:3160, 4E3, Southern Biotech) and IgG4 (1:3160, HP6025, Southern Biotech) were used as  
615 detecting antibodies. IgG1 and IgG4 anti-ADAMTS13 antibody levels were calculated based on  
616 their respective standard curves and normalized to HC controls ((TTP anti-ADAMTS13  
617 levels)/(HC anti-ADAMTS13 average levels)) (considering the background caused by non-  
618 specific IgG in plasma). Based on the relative normalized IgG1 and IgG4 anti-ADAMTS13  
619 antibody levels, TTP patients were divided into "IgG1-dominant TTP" and "IgG4-dominant  
620 TTP" groups.

621 4) To determine the total IgG, IgG1, and IgG4 anti-Dsg1 antibodies in PF and HC serum  
622 samples, recombinant Dsg1 was coated, and diluted serum samples (dilution: 1 to 100 for IgG1, 1

623 to 1000 for IgG4 and IgG) were analyzed, together with serially diluted PF24-9(IgG1) and PF24-  
624 9(IgG4) antibodies as references (0.316 µg/ml as positive controls (PC)); HRP-conjugated goat  
625 anti-human IgG Fc (1:10000, Bethyl Laboratories), mouse anti-human IgG1 (1:2000, HP6070,  
626 Thermo) and IgG4 (1:2000, HP6023, Thermo) were used as detecting antibodies; unit values of  
627 Dsg1-specific IgG, IgG1 and IgG4 antibodies were calculated according to the commercial anti-  
628 Dsg1 IgG detecting kit (Medical & Biological Laboratories) using the following formula:  
629  $(OD_{650_{\text{sample}}}-OD_{650_{\text{HC}}})/(OD_{650_{\text{PC}}}-OD_{650_{\text{HC}}}) \times \text{Dilution factor}$ .

630 5) To analyze the binding epitopes of anti-Dsg1 IgG1 and IgG4 antibodies in PF serum,  
631 recombinant human Dsg1, Dsg2 and Dsg1/2 chimeric proteins (5 µg/ml) were coated and 1:100  
632 diluted serum samples were analyzed; HRP-conjugated mouse anti-human IgG1 (1:2000,  
633 HP6070, Thermo) and IgG4 (1:2000, HP6023, Thermo) were used as detecting antibodies.

634 6) To detect the levels of free hIgG in mouse serum samples, goat anti-human IgG (H+L)  
635 (Jackson ImmunoResearch Laboratories) was coated and serum samples diluted to optimized  
636 concentration were analyzed (1:100 or 1:1000); goat anti-human IgG (H+L) HRP (1:10000,  
637 Bethyl Laboratories) or biotinylated mouse anti-human lambda chain (1:2000, JDC-12 (RUO),  
638 BD Pharmingen™) combined with Streptavidin-HRP (1:1000, BD Pharmingen™) were used as  
639 detecting antibodies for Ctrl hIgG and anti-Dsg1 IgG1 variants.

640 7) To detect the levels of Dsg1-specific immune complexes (IC), non-pathogenic PF1-2-  
641 22(IgG4) (5 µg/ml) was coated at 37°C for 6 h; diluted serum samples (1:100) were analyzed;  
642 mouse anti-hIgG1 HRP (1:3160, 4E3, Southern Biotech) was used as detecting antibody.

643 **ADAMTS13 activity assays (FRETs-VWF73)**

644 To analyze mouse ADAMTS13 activity, a published protocol (Kokame, Nobe, Kokubo,  
645 Okayama, & Miyata, 2005; Ostertag, Kacir, et al., 2016) was used with modification. Briefly, 4.8  
646  $\mu$ l of plasma sample was diluted with 25.2  $\mu$ l assay buffer (5 mM Bis-Tris, 25 mM CaCl<sub>2</sub>,  
647 0.005% Tween 20, pH = 6). Ten  $\mu$ l of the diluted sample was then transferred to a 384-well  
648 white plate (Cisbio), and mixed with 10  $\mu$ l of diluted FRETs-VW73 substrate (4  $\mu$ M, Anaspec).  
649 Related fluorescence units (RFU) of cleaved FRETs-VWF73 were measured for 1 h using a  
650 multi-mode microplate reader (Synergy H1, BioTek) with the following setting: excitation at 340  
651 nm and emission at 450 nm. Related fluorescence units (RFU) were recorded for 1 h, and their  
652 changing rates over time were calculated and expressed as "RFU/min".

### 653 **ADAMTS13 activity assay (R-CBA)**

654 ADAMTS13 activity of human plasma was assayed by evaluating collagen-binding activity  
655 (CBA) as previously described with modifications (Yue et al., 2018). In brief, 50  $\mu$ l of sodium  
656 citrate-anticoagulated plasma samples from patients and healthy controls were placed in Slide-A-  
657 Lyzer mini dialysis units (Pierce) and immersed in dialysis buffer (5 mM Tris-HCl, 0.1% Tween  
658 20, and 1.5 M urea, pH = 8.3). Dialysis was performed at 37°C for 3 h. An equal volume of the  
659 same sample was removed before dialysis and kept at room temperature during the dialysis as a  
660 control. The collagen type III binding capacities of the samples were then detected by ELISA.  
661 The data were analyzed as the fraction of CBA remaining after dialysis compared with the CBA  
662 of the individuals' baseline samples. One hundred percent minus the residual CBA was regarded  
663 as the ADAMTS13 activity.

### 664 **ADAMTS13 antigen quantification**

665 ADAMTS13 antigen levels in the plasma of HC and TTP patients were measured using Human  
666 ADAMTS13 Quantikine ELISA Kit (R&D Systems) according to the manufacturer's instructions



667 with minor modifications: (1) diluted plasma samples of HC (1:50) and TTP patients (1:2) were  
668 used; (2) the range of the standard curve was broadened to 0.78125-100 ng/ml.

### 669 **The activity of anti-ADAMTS13 antibodies in mice**

670 WT C57BL/6, hFCGR<sup>Tg</sup>, FcγRα<sup>null</sup>, or *Fcer1g*<sup>-/-</sup> mice were treated with 10 μg per mouse of  
671 TTP1-420 anti-ADAMTS13 antibodies with different constant domains  
672 (IgG1/IgG4/N297A/GASDALIE) or control hIgG (Jackson ImmunoResearch Laboratories) on  
673 day 0 through tail vein injection. Blood samples were drawn at the time points described in the  
674 results and anticoagulated with 4% sodium citrate. Plasma was obtained after centrifugation and  
675 stored at -20°C for several days before analyzing. ADAMTS13 activity was analyzed using the  
676 VWF73-FRET method described above.

### 677 **Mouse model of pemphigus foliaceus**

678 WT C57BL/6 neonatal mice born within 48 hours (SLAC, Shanghai, China) were  
679 subcutaneously injected with the same amount of control hIgG (Jackson ImmunoResearch  
680 Laboratories), IgG1 or IgG4 anti-Dsg1 autoantibodies in 50 μl (15.8 μg/mouse for PF24-9 and  
681 10 μg/mouse for PF1-8-15) and euthanized 7 hours later to collect skin samples for hematoxylin-  
682 eosin (HE) staining.

683 Adult hFCGR<sup>Tg</sup> and FcγRα<sup>null</sup> mice were treated with pathogenic anti-Dsg1 antibodies and  
684 control hIgG through tail vein injection at the dosage described in the results on day 0. Skin or  
685 ear thickness was measured by caliper; orbital blood was collected to prepare serum. After mice  
686 were euthanized, one ear was digested for flow cytometry analysis, and the other was subjected  
687 to hematoxylin-eosin (HE) staining.

688 To compare the pathogenicity of PF1-8-15(N297A) and PF1-8-15(GASDALIE) anti-Dsg1  
689 antibodies, 8-10 w old female nude mice (SLAC, Shanghai, China) were treated with 0.4-0.5  
690 mg/mouse antibodies (as specified in Figure legends) via tail vein injection on day 0. On day 2  
691 and 4, photographs were taken to record skin lesions, and blood was drawn to prepare serum.  
692 The levels of free anti-Dsg1 antibodies and Dsg1-specific ICs were analyzed in serum samples.  
693 To study the impact of non-pathogenic anti-Dsg1 antibodies (PF1-2-22) optimized for Fc-FcγR  
694 interaction, pathogenic PF1-8-15(N297A) anti-Dsg1 antibodies (0.4-0.5 mg/mouse, as specified  
695 in Figure legends) were injected to 7-9 w male nude mice (SLAC, Shanghai, China) with or  
696 without an equal amount of non-pathogenic PF1-2-22(GASDALIE) antibodies. Cutaneous  
697 lesions were recorded on day 2, and skin samples were harvested for histopathology examination  
698 and TUNEL assay after mice were sacrificed.

### 699 **Flow cytometry analysis**

700 Mouse ears were cut and split into dorsal/ventral surfaces with forceps and digested with 2 ml of  
701 dispase II solution (2.5 mg/ml in PBS with 2% FBS, Roche) in 6-well plate at 37 °C for 90 min  
702 with shaking. After separating dermis from the epidermis using forceps, tissues (both epidermis  
703 and dermis) were cut into tiny pieces and put into RPMI 1640 complete medium (RPMI 1640,  
704 10% FBS, 1% Pen/Strep) containing 0.5 mg/ml of collagenase IV (Sigma/biosharp) and 100  
705 U/ml of DNase I (Sigma) for incubating at 37°C for 60 min to complete the digestion. The  
706 digested tissue was then passed through a 70 μm cell strainer, and the debris was ground and  
707 washed through the cell strainer using 35 ml of cold PBS. Cells were collected and resuspended  
708 with 600 μl FACS buffer (PBS buffer with 0.5% FBS and 2 mM EDTA). Half of the  
709 resuspended ear cells were stained with 1 μg/ml of Alexa Fluor 700 conjugated mouse anti-  
710 mouse CD45.2 (104, BD), APC conjugated rat anti-mouse CD11b (M1/70, eBioscience) and

711 FITC conjugated rat anti-mouse Gr1 (RB6-8C5, eBioscience). DAPI (0.5 µg/ml, Invitrogen) and  
712 CountBright™ Absolute Counting Bead (3 µl/sample, Life technologies) were added to  
713 resuspend cells before analyzing using a BD LSRFortessa™ X-20 analyzer (BD Biosciences).  
714 Data were analyzed using FlowJo X. Gating strategy was shown in Fig. S8.

#### 715 **TUNEL assay**

716 TUNEL staining was conducted per manufacturer instructions (Roche). Images were obtained  
717 via OLYMPUS BX51 Confocal Microscope outfitted with a 10x or 40x objective. Apoptotic  
718 cells were defined as cells possessing a TUNEL positive (green) pyknotic nucleus.

#### 719 **Statistics**

720 Statistical analyses were performed with Prism GraphPad 6.0, and p values less than 0.05 were  
721 considered to be statistically significant. Asterisks indicate statistical difference within two  
722 interested groups on the figures (\* p < 0.05. \*\* p < 0.01, \*\*\* p < 0.001, \*\*\*\* p < 0.0001).

#### 723 **Study approval**

724 Ethical approval was obtained from the Ethics Committees in The Rui Jin Hospital of Shanghai  
725 Jiao Tong University School of Medicine and The First Affiliated Hospital of Soochow  
726 University, respectively. All PF and TTP patients and healthy volunteers signed informed  
727 consent. All mice were bred and maintained under specific pathogen-free (SPF) conditions, and  
728 all animal experiments were performed under the institutional guidelines of the Shanghai Jiao  
729 Tong University School of Medicine Institutional Animal Care and Use Committee.

730

731 **Author contributions**

732 F.L., Y.M.Z, and Y.B. designed the experiments; J.S., S.Z. and Y.B. collected the human  
733 samples; Y.B., J.S., Y.Z., Y.J.Z., H.Z., and M.L. performed experiments. A.Z., and J.S. provided  
734 technical supports; F.L., Y.M.Z, and Y.B. analyzed results, F.L., Y.M.Z, M.P., and Y.B. wrote  
735 the paper.

736 **Acknowledgments**

737 We thank Dr. Jeffrey Ravetch of The Rockefeller University for providing FcγR-deficient mouse  
738 (FcγRα<sup>null</sup>), FcγR-humanized mouse (hFCGR<sup>Tg</sup>) and Fc receptor common γ-chain deficient  
739 mouse (*FcγR1g*<sup>-/-</sup>), and pFL\_DEC expression vector. We acknowledge the assistance of staff in  
740 the Department of Laboratory Animal Science, Shanghai Jiao Tong University School of  
741 Medicine and Shanghai Institute of Immunology. **Funding:** This work was supported by NNSFC  
742 projects No. 31422020 and 31870924. Y.M.Z. is supported by NNSFC project No. 81873431  
743 and Jiangsu Provincial Natural Science Foundation No. BK20181164. Y.Z. is supported by  
744 Shanghai Sailing Program No. 16YF1409700. H.Z. is supported by Shanghai Municipal Natural  
745 Science Foundation project No. 15ZR1436400 and Shanghai Young Oriental scholar program  
746 2015 by Shanghai Municipal Education Commission. F.L., Y.Z., and H.Z. are also supported by  
747 the innovative research team of high-level local universities in Shanghai (SSMU-  
748 2DCX20180100).

749 **Competing interests:** A patent application based on the study is being prepared for submission,  
750 and Fubin Li, Yanxia Bi, Yan Zhang, and Huihui Zhang are listed as inventors.

751

752 **References**

- 753 Akdis, C. A., & Akdis, M. (2011). Mechanisms of allergen-specific immunotherapy. *J Allergy*  
754 *Clin Immunol*, 127(1), 18-27; quiz 28-19. doi:10.1016/j.jaci.2010.11.030
- 755 Anhalt, G. J., Labib, R. S., Voorhees, J. J., Beals, T. F., & Diaz, L. A. (1982). Induction of  
756 pemphigus in neonatal mice by passive transfer of IgG from patients with the disease. *N*  
757 *Engl J Med*, 306(20), 1189-1196. doi:10.1056/NEJM198205203062001
- 758 Aoki, V., Rivitti, E. A., Diaz, L. A., & Cooperative Group on Fogo Selvagem, R. (2015). Update  
759 on fogo selvagem, an endemic form of pemphigus foliaceus. *J Dermatol*, 42(1), 18-26.  
760 doi:10.1111/1346-8138.12675
- 761 Beers, S. A., Glennie, M. J., & White, A. L. (2016). Influence of immunoglobulin isotype on  
762 therapeutic antibody function. *Blood*, 127(9), 1097-1101. doi:10.1182/blood-2015-09-  
763 625343
- 764 Bettoni, G., Palla, R., Valsecchi, C., Consonni, D., Lotta, L. A., Trisolini, S. M., . . . Peyvandi, F.  
765 (2012). ADAMTS-13 activity and autoantibodies classes and subclasses as prognostic  
766 predictors in acquired thrombotic thrombocytopenic purpura. *J Thromb Haemost*, 10(8),  
767 1556-1565. doi:10.1111/j.1538-7836.2012.04808.x
- 768 Bournazos, S., DiLillo, D. J., Goff, A. J., Glass, P. J., & Ravetch, J. V. (2019). Differential  
769 requirements for FcγR engagement by protective antibodies against Ebola virus.  
770 *Proc Natl Acad Sci U S A*, 116(40), 20054-20062. doi:10.1073/pnas.1911842116
- 771 Bournazos, S., & Ravetch, J. V. (2017). Diversification of IgG effector functions. *Int Immunol*,  
772 29(7), 303-310. doi:10.1093/intimm/dxx025

- 773 Clynes, R., Dumitru, C., & Ravetch, J. V. (1998). Uncoupling of immune complex formation and  
774 kidney damage in autoimmune glomerulonephritis. *Science*, *279*(5353), 1052-1054.  
775 doi:10.1126/science.279.5353.1052
- 776 Clynes, R., Takechi, Y., Moroi, Y., Houghton, A., & Ravetch, J. V. (1998). Fc receptors are  
777 required in passive and active immunity to melanoma. *Proc Natl Acad Sci U S A*, *95*(2),  
778 652-656. doi:10.1073/pnas.95.2.652
- 779 Dahan, R., Segal, E., Engelhardt, J., Selby, M., Korman, A. J., & Ravetch, J. V. (2015).  
780 FcγR3 Modulate the Anti-tumor Activity of Antibodies Targeting the PD-1/PD-L1  
781 Axis. *Cancer Cell*, *28*(3), 285-295. doi:10.1016/j.ccell.2015.08.004
- 782 Devey, M. E., Lee, S. R., Richards, D., & Kemeny, D. M. (1989). Serial studies on the functional  
783 affinity and heterogeneity of antibodies of different IgG subclasses to phospholipase A2  
784 produced in response to bee-venom immunotherapy. *J Allergy Clin Immunol*, *84*(3), 326-  
785 330. doi:10.1016/0091-6749(89)90416-8
- 786 Ding, X., Diaz, L. A., Fairley, J. A., Giudice, G. J., & Liu, Z. (1999). The anti-desmoglein 1  
787 autoantibodies in pemphigus vulgaris sera are pathogenic. *J Invest Dermatol*, *112*(5),  
788 739-743. doi:10.1046/j.1523-1747.1999.00585.x
- 789 Ferrari, S., Mudde, G. C., Rieger, M., Veyradier, A., Kremer Hovinga, J. A., & Scheiflinger, F.  
790 (2009). IgG subclass distribution of anti-ADAMTS13 antibodies in patients with  
791 acquired thrombotic thrombocytopenic purpura. *J Thromb Haemost*, *7*(10), 1703-1710.  
792 doi:10.1111/j.1538-7836.2009.03568.x
- 793 Ferrari, S., Palavra, K., Gruber, B., Kremer Hovinga, J. A., Knobl, P., Caron, C., . . .  
794 Scheiflinger, F. (2014). Persistence of circulating ADAMTS13-specific immune

795 complexes in patients with acquired thrombotic thrombocytopenic purpura.  
796 *Haematologica*, 99(4), 779-787. doi:10.3324/haematol.2013.094151

797 Feys, H. B., Roodt, J., Vandeputte, N., Pareyn, I., Lamprecht, S., van Rensburg, W. J., . . .  
798 Vanhoorelbeke, K. (2010). Thrombotic thrombocytopenic purpura directly linked with  
799 ADAMTS13 inhibition in the baboon (*Papio ursinus*). *Blood*, 116(12), 2005-2010.  
800 doi:10.1182/blood-2010-04-280479

801 Furtado, T. A. (1959). Histopathology of pemphigus foliaceus. *AMA Arch Derm*, 80(1), 66-71.  
802 doi:10.1001/archderm.1959.01560190068010

803 Gaipf, U. S., Kuhn, A., Sheriff, A., Munoz, L. E., Franz, S., Voll, R. E., . . . Herrmann, M.  
804 (2006). Clearance of apoptotic cells in human SLE. *Curr Dir Autoimmun*, 9, 173-187.  
805 doi:10.1159/000090781

806 Gerritsen, H. E., Turecek, P. L., Schwarz, H. P., Lammle, B., & Furlan, M. (1999). Assay of von  
807 Willebrand factor (vWF)-cleaving protease based on decreased collagen binding affinity  
808 of degraded vWF: a tool for the diagnosis of thrombotic thrombocytopenic purpura  
809 (TTP). *Thromb Haemost*, 82(5), 1386-1389.

810 Hammers, C. M., & Stanley, J. R. (2020). Recent Advances in Understanding Pemphigus and  
811 Bullous Pemphigoid. *J Invest Dermatol*, 140(4), 733-741. doi:10.1016/j.jid.2019.11.005

812 Huijbers, M. G., Plomp, J. J., van der Maarel, S. M., & Verschuuren, J. J. (2018). IgG4-mediated  
813 autoimmune diseases: a niche of antibody-mediated disorders. *Ann N Y Acad Sci*,  
814 1413(1), 92-103. doi:10.1111/nyas.13561

815 Ishii, K., Lin, C., Siegel, D. L., & Stanley, J. R. (2008). Isolation of pathogenic monoclonal anti-  
816 desmoglein 1 human antibodies by phage display of pemphigus foliaceus autoantibodies.  
817 *J Invest Dermatol*, 128(4), 939-948. doi:10.1038/sj.jid.5701132

- 818 Ji, H., Ohmura, K., Mahmood, U., Lee, D. M., Hofhuis, F. M., Boackle, S. A., . . . Mathis, D.  
819 (2002). Arthritis critically dependent on innate immune system players. *Immunity*, *16*(2),  
820 157-168. doi:10.1016/s1074-7613(02)00275-3
- 821 Kokame, K., Nobe, Y., Kokubo, Y., Okayama, A., & Miyata, T. (2005). FRET-S-VWF73, a first  
822 fluorogenic substrate for ADAMTS13 assay. *Br J Haematol*, *129*(1), 93-100.  
823 doi:10.1111/j.1365-2141.2005.05420.x
- 824 Koneczny, I. (2018). A New Classification System for IgG4 Autoantibodies. *Front Immunol*, *9*,  
825 97. doi:10.3389/fimmu.2018.00097
- 826 Korman, N. J., Eyre, R. W., Klaus-Kovtun, V., & Stanley, J. R. (1989). Demonstration of an  
827 adhering-junction molecule (plakoglobin) in the autoantigens of pemphigus foliaceus and  
828 pemphigus vulgaris. *N Engl J Med*, *321*(10), 631-635.  
829 doi:10.1056/NEJM198909073211002
- 830 Li, N., Aoki, V., Hans-Filho, G., Rivitti, E. A., & Diaz, L. A. (2003). The role of intramolecular  
831 epitope spreading in the pathogenesis of endemic pemphigus foliaceus (fogo selvagem). *J*  
832 *Exp Med*, *197*(11), 1501-1510. doi:10.1084/jem.20022031
- 833 Lighaam, L. C., & Rispens, T. (2016). The Immunobiology of Immunoglobulin G4. *Semin Liver*  
834 *Dis*, *36*(3), 200-215. doi:10.1055/s-0036-1584322
- 835 Liu, X., Zhao, Y., Shi, H., Zhang, Y., Yin, X., Liu, M., . . . Li, F. (2019). Human  
836 immunoglobulin G hinge regulates agonistic anti-CD40 immunostimulatory and  
837 antitumour activities through biophysical flexibility. *Nat Commun*, *10*(1), 4206.  
838 doi:10.1038/s41467-019-12097-6



- 839 McGaha, T. L., Sorrentino, B., & Ravetch, J. V. (2005). Restoration of tolerance in lupus by  
840 targeted inhibitory receptor expression. *Science*, *307*(5709), 590-593.  
841 doi:10.1126/science.1105160
- 842 Nagata, S. (2018). Apoptosis and Clearance of Apoptotic Cells. *Annu Rev Immunol*, *36*, 489-517.  
843 doi:10.1146/annurev-immunol-042617-053010
- 844 Ostertag, E. M., Bdeir, K., Kacir, S., Thiboutot, M., Gulendran, G., Yunk, L., . . . Siegel, D. L.  
845 (2016). ADAMTS13 autoantibodies cloned from patients with acquired thrombotic  
846 thrombocytopenic purpura: 2. Pathogenicity in an animal model. *Transfusion*, *56*(7),  
847 1775-1785. doi:10.1111/trf.13583
- 848 Ostertag, E. M., Kacir, S., Thiboutot, M., Gulendran, G., Zheng, X. L., Cines, D. B., & Siegel, D.  
849 L. (2016). ADAMTS13 autoantibodies cloned from patients with acquired thrombotic  
850 thrombocytopenic purpura: 1. Structural and functional characterization in vitro.  
851 *Transfusion*, *56*(7), 1763-1774. doi:10.1111/trf.13584
- 852 Rados, J. (2011). Autoimmune blistering diseases: histologic meaning. *Clin Dermatol*, *29*(4),  
853 377-388. doi:10.1016/j.clindermatol.2011.01.007
- 854 Rihet, P., Demeure, C. E., Dessein, A. J., & Bourgois, A. (1992). Strong serum inhibition of  
855 specific IgE correlated to competing IgG4, revealed by a new methodology in subjects  
856 from a *S. mansoni* endemic area. *Eur J Immunol*, *22*(8), 2063-2070.  
857 doi:10.1002/eji.1830220816
- 858 Rock, B., Labib, R. S., & Diaz, L. A. (1990). Monovalent Fab' immunoglobulin fragments from  
859 endemic pemphigus foliaceus autoantibodies reproduce the human disease in neonatal  
860 Balb/c mice. *J Clin Invest*, *85*(1), 296-299. doi:10.1172/JCI114426

- 861 Rock, B., Martins, C. R., Theofilopoulos, A. N., Balderas, R. S., Anhalt, G. J., Labib, R. S., . . .  
862 Diaz, L. A. (1989). The pathogenic effect of IgG4 autoantibodies in endemic pemphigus  
863 foliaceus (fogo selvagem). *N Engl J Med*, *320*(22), 1463-1469.  
864 doi:10.1056/NEJM198906013202206
- 865 Sazinsky, S. L., Ott, R. G., Silver, N. W., Tidor, B., Ravetch, J. V., & Wittrup, K. D. (2008).  
866 Aglycosylated immunoglobulin G1 variants productively engage activating Fc receptors.  
867 *Proc Natl Acad Sci U S A*, *105*(51), 20167-20172. doi:10.1073/pnas.0809257105
- 868 Schmidt, E., Kasperkiewicz, M., & Joly, P. (2019). Pemphigus. *Lancet*, *394*(10201), 882-894.  
869 doi:10.1016/S0140-6736(19)31778-7
- 870 Schumacher, M. J., Egen, N. B., & Tanner, D. (1996). Neutralization of bee venom lethality by  
871 immune serum antibodies. *Am J Trop Med Hyg*, *55*(2), 197-201.  
872 doi:10.4269/ajtmh.1996.55.197
- 873 Shiokawa, M., Kodama, Y., Kuriyama, K., Yoshimura, K., Tomono, T., Morita, T., . . . Chiba, T.  
874 (2016). Pathogenicity of IgG in patients with IgG4-related disease. *Gut*, *65*(8), 1322-  
875 1332. doi:10.1136/gutjnl-2015-310336
- 876 Sinkovits, G., Szilagyi, A., Farkas, P., Inotai, D., Szilvasi, A., Tordai, A., . . . Prohaszka, Z.  
877 (2018). Concentration and Subclass Distribution of Anti-ADAMTS13 IgG  
878 Autoantibodies in Different Stages of Acquired Idiopathic Thrombotic  
879 Thrombocytopenic Purpura. *Front Immunol*, *9*, 1646. doi:10.3389/fimmu.2018.01646
- 880 Smith, P., DiLillo, D. J., Bournazos, S., Li, F., & Ravetch, J. V. (2012). Mouse model  
881 recapitulating human Fcγ receptor structural and functional diversity. *Proc Natl*  
882 *Acad Sci U S A*, *109*(16), 6181-6186. doi:10.1073/pnas.1203954109

- 883 Spindler, V., Eming, R., Schmidt, E., Amagai, M., Grando, S., Jonkman, M. F., . . . Waschke, J.  
884 (2018). Mechanisms Causing Loss of Keratinocyte Cohesion in Pemphigus. *J Invest*  
885 *Dermatol*, 138(1), 32-37. doi:10.1016/j.jid.2017.06.022
- 886 Takai, T., Li, M., Sylvestre, D., Clynes, R., & Ravetch, J. V. (1994). FcR gamma chain deletion  
887 results in pleiotrophic effector cell defects. *Cell*, 76(3), 519-529. doi:10.1016/0092-  
888 8674(94)90115-5
- 889 Umehara, H., Okazaki, K., Nakamura, T., Satoh-Nakamura, T., Nakajima, A., Kawano, M., . . .  
890 Chiba, T. (2017). Current approach to the diagnosis of IgG4-related disease -  
891 Combination of comprehensive diagnostic and organ-specific criteria. *Mod Rheumatol*,  
892 27(3), 381-391. doi:10.1080/14397595.2017.1290911
- 893 van der Neut Kolfschoten, M., Schuurman, J., Losen, M., Bleeker, W. K., Martinez-Martinez, P.,  
894 Vermeulen, E., . . . Parren, P. W. (2007). Anti-inflammatory activity of human IgG4  
895 antibodies by dynamic Fab arm exchange. *Science*, 317(5844), 1554-1557.  
896 doi:10.1126/science.1144603
- 897 Vidarsson, G., Dekkers, G., & Rispens, T. (2014). IgG subclasses and allotypes: from structure  
898 to effector functions. *Front Immunol*, 5, 520. doi:10.3389/fimmu.2014.00520
- 899 Warren, S. J., Arteaga, L. A., Rivitti, E. A., Aoki, V., Hans-Filho, G., Qaqish, B. F., . . . Diaz, L.  
900 A. (2003). The role of subclass switching in the pathogenesis of endemic pemphigus  
901 foliaceus. *J Invest Dermatol*, 120(1), 104-108. doi:10.1046/j.1523-1747.2003.12017.x
- 902 Yamagami, J., Kacir, S., Ishii, K., Payne, A. S., Siegel, D. L., & Stanley, J. R. (2009). Antibodies  
903 to the desmoglein 1 precursor proprotein but not to the mature cell surface protein cloned  
904 from individuals without pemphigus. *J Immunol*, 183(9), 5615-5621.  
905 doi:10.4049/jimmunol.0901691

- 906 Yoshida, K., Ishii, K., Shimizu, A., Yokouchi, M., Amagai, M., Shiraishi, K., . . . Ishiko, A.  
907 (2017). Non-pathogenic pemphigus foliaceus (PF) IgG acts synergistically with a directly  
908 pathogenic PF IgG to increase blistering by p38MAPK-dependent desmoglein 1  
909 clustering. *J Dermatol Sci*, 85(3), 197-207. doi:10.1016/j.jdermsci.2016.12.010
- 910 Yuan, H., Zhou, S., Liu, Z., Cong, W., Fei, X., Zeng, W., . . . Pan, M. (2017). Pivotal Role of  
911 Lesional and Perilesional T/B Lymphocytes in Pemphigus Pathogenesis. *J Invest*  
912 *Dermatol*, 137(11), 2362-2370. doi:10.1016/j.jid.2017.05.032
- 913 Yue, C., Su, J., Gao, R., Wen, Y., Li, C., Chen, G., . . . Li, X. (2018). Characteristics and  
914 Outcomes of Patients with Systemic Lupus Erythematosus-associated Thrombotic  
915 Microangiopathy, and Their Acquired ADAMTS13 Inhibitor Profiles. *J Rheumatol*,  
916 45(11), 1549-1556. doi:10.3899/jrheum.170811
- 917 Zheng, X. L. (2015). ADAMTS13 and von Willebrand factor in thrombotic thrombocytopenic  
918 purpura. *Annu Rev Med*, 66, 211-225. doi:10.1146/annurev-med-061813-013241
- 919 Zhou, S., Liu, Z., Yuan, H., Zhao, X., Zou, Y., Zheng, J., & Pan, M. (2019). Autoreactive B Cell  
920 Differentiation in Diffuse Ectopic Lymphoid-Like Structures of Inflamed Pemphigus  
921 Lesions. *J Invest Dermatol*. doi:10.1016/j.jid.2019.07.717
- 922